Upcoming Webinar
BRAF V600E NSCLC: Updated Evidence for Encorafenib + Binimetinib
Date: December 15, 2025 | 5:00 PM
When: Monday, December 15 | 5 p.m. EST
Presenters: Stephanie McDonald, FNP-BC, AOCNP | Dana-Farber Cancer Institute
Targeted therapy for BRAF V600E–mutant NSCLC is advancing quickly, and the latest PHAROS data is shaping how clinicians approach treatment decisions.
In this session, Stephanie McDonald breaks down what the newest evidence means for real-world practice, from updated efficacy and safety findings with encorafenib + binimetinib to where guidelines place this regimen in the first-line setting.
Get Insight Into:
- What the updated PHAROS data reveals about the efficacy and safety of encorafenib + binimetinib in BRAF V600E–mutant metastatic NSCLC
- How current clinical guidelines support targeted therapy in the first-line setting and how to apply them in everyday practice
- Which adverse events to anticipate early and strategies for proactive AE mitigation and patient support
- How NCODA’s PQI resource helps streamline decision-making, improve supportive care, and guide more coordinated patient management
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
BRAF V600E NSCLC: Updated Evidence for Encorafenib + Binimetinib
December 15, 2025 | 5:00 PM